Skip to Content

AJCC 8th Edition of Lung Cancer Staging: Emphasis on Multiple Lung Carcinomas

Overview

In the 8th edition of the American Joint Committee on Cancer (AJCC) lung cancer staging manual, several changes have been introduced, primarily affecting the T descriptor. These changes revolve around the introduction of adenocarcinoma in situ, minimally invasive adenocarcinoma, and adenocarcinoma with predominant lepidic pattern in the last World Health Organization’s classification of lung tumors. Furthermore, a special subcommittee of the International Association for the Study of Lung Cancer was formed to address ambiguity and problems of classifying and staging multiple lung tumors. These new concepts will be reviewed in this presentation.

 

Presentation

View the Archived Webinar

Length of Video: 51 minutes

 

Presenter

Image of Marie Christine Aubry, M.D.Marie Christine Aubry, M.D.
Professor of Laboratory Medicine and Pathology
Anatomic Pathology
Mayo Clinic, Rochester, Minnesota

 

 

 

 

Learning Objectives

1. Describe the new T descriptors, especially as they pertain to sub-solid tumors.
2. Discuss how the staging of multiple lung carcinomas varies with the clinical scenarios.
3. Recognize the different clinical scenarios and the related staging scheme.
4. Review the importance and limitations of a pathologist’s interpretation in staging multiple lung carcinomas.
5. Explain the role and limitations of ancillary studies in distinguishing independent primaries from intrapulmonary metastasis.

 

Intended Audience

This webinar is designed for pathologists.

 

Level of instruction

Basic

 

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

 

National Physician Payment Transparency Program

This webinar is designed for Mayo Medical Laboratories is not an applicable manufacturer or applicable group purchasing organization (GPO). (GPOs, per the Centers for Medicare & Medicaid Services, and this program do not trigger any reporting requirements pursuant to Open Payments [Sunshine Act] legislation.)

 

Note: No credit is offered for this Specialty Testing presentation.

MCL Education

MCL Education

This post was developed by our Education and Technical Publications Team.